Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin Alfa in MASH (ZENITH-1)
NCT07221227Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 3 trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by GSK. Started Oct 2025; status: recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07221227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221227.